Pharmarise Holdings Corporation
Financial Summary for the First Quarter of May Term, 9th Year of Reiwa (Japan GAAP) (Consolidated)
Consolidated net sales for the first quarter increased year over year to 17,242 million yen, operating loss of 68 million yen, ordinary loss of 79 million yen, and net loss attributable to owners of the parent of 36 million yen. Although the pharmaceutical dispensing segment contributed to higher sales, overall profitability deteriorated due to higher cost rates. The full-year outlook is currently unchanged.
Key Figures
- Net sales: 17,242 million yen (YoY +2.9%)
- Operating income: 68 million yen (YoY △54.8%)
- Net income attributable to owners of the parent: △36 million yen (YoY △18)
AI要約
Overview of results
In the first quarter of this term, sales increased year over year, but operating income, ordinary income, and net income declined into loss due to higher cost ratios driven by the dispensing pharmacy business and the impact of revisions to dispensing fees and drug prices. By segment, dispensing pharmacies contributed to sales growth, but profitability did not improve overall. The group will continue to solidify the medium-term plan “Make a Leap 2027,” focusing on strengthening home and facility dispensing and advancing M&A integration processes.
Outlook and impact on investors
The full-year forecast remains unchanged (May period 9th year), but there is a possibility that cost ratio increases and revisions to drug prices and dispensing fees will continue to affect results. In the long term, revenue growth and profit improvements are targeted through contributions from new stores and the advancement of post-M&A integration. Investors should monitor the profitability of the dispensing pharmacy business and the status of home and facility dispensing opportunities.
Revenue Trend
Operating Income Trend
Segment Revenue by Segment
Profit Margin Analysis
Pharmarise Holdings Corporation
Company overview · Stock price · Financial data · All IR
